Biopharmaceutical Research Consortium Structure and Governance
CQDM operates through its representative bodies: the Board of Directors and its committees, officers, members and other representatives.
Board of Directors
The Board of Directors and its five sub-committees are largely responsible for the governance of the biopharmaceutical research consortium. Members of the Board meet four times per year and oversee the sound management of the biopharmaceutical research consortium. They ensure that financial matters are dealt with carefully and independently, in compliance with the selection criteria of each funding program maintained by CQDM.
Members of the Board of Directors represent all stakeholders of the biopharmaceutical research consortium and draw on their extensive experience to help CQDM maximize the impact of funded projects and reach its objectives.
Chairman
Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation
Observers
Yvon Fréchette
Innovation Advisor
Collaborative Research Department
Ministry of Economy and Innovation (MEI)
Secretary
François Painchaud
Lawyer, Partner,
ROBIC, LLP
Members
Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada
Diane Gosselin
President and Chief Executive Officer,
CQDM
Daniel Hétu
Managing Director,
Lumira Ventures
Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)
Sarah Jenna
Co-founder and CEO,
My Intelligent Machines (MIMs)
Frédéric Ors
Biotech Executive
Ken Pastor
General Partner,
CTI Capital
Louise Proulx
Corporate Director
Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures
Rémi Quirion
Chief Scientist of Quebec
Uwe Schoenbeck
Senior VP & Chief Scientific Officer, External R&D Innovation,
Pfizer worldwide R&D
Philip Tagari
Vice-President – Research
Amgen Inc.
Executive Committee
The Executive Committee meets regularly to settle specific aspects of the biopharmaceutical research consortium’s business activities.
Chairman
Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation
Members
Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada
Diane Gosselin
President and Chief Executive Officer,
CQDM
Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)
Ken Pastor
General Partner,
CTI Capital
Louise Proulx
Corporate Director
Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures
Audit Committee
The Audit Committee is a sub-committee of the Board that meets at least twice per year to review the financial statements and receive notification of any errors or misstatements contained in financial statements from the external auditors.
Chairman
Ken Pastor
General Partner,
CTI Capital
Members
Richard Fajzel
Chief Executive Officer,
Exactis Innovation
Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures
Daniel Hétu
Managing Director,
Lumira Ventures
Corporate Governance and Nominating Committee
The Corporate Governance and Nominating Committee ensures that the best resources and members are supporting the structure and governance of the biopharmaceutical research consortium.
The Committee oversees the recruitment, resignation and replacement process of new Board members. Its ultimate goal is to help CQDM focus on executing its strategy, while leveraging the experience of the Board.
Chairman
Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation
Members
Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)
Diane Gosselin
President and Chief Executive Officer,
CQDM
Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures
Scientific Advisory Board
The Scientific Advisory Board was created by the Board of Directors and is comprised of experienced and independent scientists. The members examine all external scientific reviews obtained by CQDM, ensure that projects targeted for funding meet all selection criteria and present their recommendations to the Board of Directors. The Scientific Advisory Board is the reason why CQDM can testify that it maintains a stringent selection process that maximizes positive R&D impacts for its members.
Chairman
Brian Underdown
Biotechnology Consultant,
BJUConsulting
Observers
Catherine Richard
Advisor, Industrial Partnerships,
Quebec Ministry of Economy and Innovation (MEI)
Diane Gosselin
President and Chief Executive Officer,
CQDM
Members
David Bouffard
PMT (Personalize my Treatment) Director
Exactis Innovation
Christine Brideau
Vice President of In Vitro Pharmacology
Deerfield Discovery and Development, LLC
André Darveau
Executive Vice Rector and Vice Rector, Human Resources and Finance
Université Laval
Benjamin Haibe-Kains
Senior Scientist
Princess Margaret Cancer Centre – University Health Network
Mark Lim
Vice President | Research, Discovery, and Innovation
ASN Alliance for Kidney Health
Cameron Black
Executive Vice President Discovery
Repare Therapeutics
John Delaney
Biotechnology Sr. Advisor
Jennifer Hamilton
Life sciences consultant
Kuldeep Neote
Entrepreneur In Residence
National Institutes of Health & FACIT/OICR
